Homepage Top Section2

The study has achieved the primary endpoint by demonstrating Kadcyla as a single agent significantly reduced the risk of disease recurrence or death compared to Herceptin as an

The regulator’s Oncologic Drugs Advisory Committee voted unanimously recommending approval of CT-P10, a proposed monoclonal antibody (mAb) biosimilar to Rituxan, to treat adult patients in three proposed indications.

Cinfa Biotech, which was founded in 2013, has offices in Munich, Germany and Pamplona, Spain. The company, which is part of Spanish pharma firm Cinfa Group, is engaged

The trial showed that Stelara induced clinical remission in a significantly greater proportion of UC patients at week 8 compared to placebo at both doses studied. Major secondary

Merck’s supplemental application has been approved to expand the use of Gardasil 9, which helps in preventing certain cancers and diseases caused by the nine HPV types covered

As per terms of the deal, Boston Pharmaceuticals purchased global rights to two complementary candidates targeting carbapenem-resistant enterobacteriaceae (CRE) and one candidate targeting Pseudomonas. The  anti-infective drug candidates

Libtayo is a fully-human monoclonal antibody that targets the immune checkpoint receptor PD-1 (programmed cell death protein-1), and is claimed to be the first and only treatment specifically

In November 2014, Janssen signed an exclusive worldwide collaboration and license agreement with Geron for the development and commercialization of imetelstat in oncology, including hematologic myeloid malignancies. Janssen

Based in Boston of Massachusetts, Syntimmune is engaged in the development of differentiated drug candidates in a range of autoimmune diseases. As per terms of the deal, Alexion